Sutro has collaborated with Celgene since 2012 on the discovery and preclinical development of Antibody Drug Conjugates and bispecific antibodies. In August 2017 Sutro announced that it was refocusing its 2014 immuno-oncology collaboration with Celgene on four programs that are advancing through preclinical development, including an antibody drug conjugate (ADC) program targeting B-Cell maturation antigen (BCMA) previously disclosed by Celgene. Sutro may also produce both GLP and cGMP material as the BCMA ADC program progresses.
In September, 2014, Sutro announced a $300M+ collaboration with EMD Serono to discover and develop novel antibody drug conjugates for several targets in the field of oncology. Sutro is responsible for identifying lead molecules and producing both preclinical and clinical material using its Xpress CF+™ platform.
If you are interested in exploring partnership opportunities with Sutro, contact us at firstname.lastname@example.org